Most Favored Nation - Vital Signs

Sign in Subscribe

Most Favored Nation

A collection of 6 posts

EMA sets out process to appoint next Executive Director

EMA sets out process to appoint next Executive Director

EMA’s September Management Board meeting advanced the process for appointing its next Executive Director while reviewing preparations for new EU pharmaceutical legislation

Inside EU Health: MFN; €84.8 million health innovation call; medical countermeasures; UK/US deal could cost more lives than COVID

Inside EU Health

Inside EU Health: MFN; €84.8 million health innovation call; medical countermeasures; UK/US deal could cost more lives than COVID

Can the EU resist US pressure on medicine prices? €84.8m launches call to support healthy ageing, reduced animal testing and early-stage innovation; EU seeks partners to shape new medical countermeasures preparedness network; UK deal with US could cost more lives than COVID

Can the EU resist US pressure on medicine prices?

Most Favored Nation

Can the EU resist US pressure on medicine prices?

At European consumer group BEUC event, speakers say the EU must stand firm against US demands for higher drug prices

EU health ministers may demand further review of Urban Wastewater rules

EU health ministers may demand further review of Urban Wastewater rules

Tomorrow, health ministers will discuss an agreed position on the European Biotech Act I directive, but the real discussions may lie elsewhere

Inside EU Health: Co-ordinated pricing and reimbursement; Biotech Act SPC; COVID-19 contracts

Inside EU Health

Inside EU Health: Co-ordinated pricing and reimbursement; Biotech Act SPC; COVID-19 contracts

Beneluxa Initiative calls for pricing and reimbursement coordination; EFPIA argues that the Biotech Act 12-month extension to SPC is too narrow ; AG recommends dismissing Commission appeal on COVID-19 contract access

NGOs challenge UK-US medicines pricing deal

Most Favored Nation

NGOs challenge UK-US medicines pricing deal

NGOs accuse the British government of trading NHS pricing safeguards for export protection, as Washington intensifies efforts to push higher medicine costs across Europe